Biomarkers in Cardiology - Part 1 - In Heart Failure and Specific Cardiomyopathies

,

doi:10.5935/abc.20140184

Cited by 8 publications

(5 citation statements)

References 47 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New biomarkers are warranted and have been explored in recent reports. 42 , 43 More than one decade ago, NPs emerged as the first biomarkers for the diagnosis of acute HF. 44 , 45 Since then, this is the most promising biomarker for the management of such patients, adding to NPs, especially for guiding therapy.…”

Section: Discussionmentioning

confidence: 99%

Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure

Villacorta¹,

Maisel²

2015

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

ST2 is a member of the interleukin-1 receptor family biomarker and circulating soluble ST2 concentrations are believed to reflect cardiovascular stress and fibrosis. Recent studies have demonstrated soluble ST2 to be a strong predictor of cardiovascular outcomes in both chronic and acute heart failure. It is a new biomarker that meets all required criteria for a useful biomarker. Of note, it adds information to natriuretic peptides (NPs) and some studies have shown it is even superior in terms of risk stratification. Since the introduction of NPs, this has been the most promising biomarker in the field of heart failure and might be particularly useful as therapy guide.

show abstract

Section: Discussionmentioning

confidence: 99%

Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure

Villacorta¹,

Maisel²

2015

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

show abstract

“…Myocardial injury secondary to MI not only induces morphological changes in the infarcted area but also causes LV eccentric hypertrophy 14,15 . In response to cardiac injury following MI, cellular and molecular alterations occurring in the infarcted area yield ventricular dysfunction and malignant ventricular arrhythmias [16][17][18] . According to previous reports, up to 50% of patients who suffer from ventricular dysfunction will die within 5 years following MI.…”

Section: Discussionmentioning

confidence: 99%

Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients

Tezcan

Tunçez

Demir

et al. 2023

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Objective: Myocardial infarction has unfavorable effect on structural and functional properties of the myocardium, referred to as cardiac remodeling. Left ventricular mass, left ventricular mass index, and relative wall thickness are important predictors of cardiac remodeling. In this study, we investigated the effect of candesartan treatment in comparison with zofenopril treatment on echocardiographic indices of cardiac remodeling in post myocardial infarction patients. Material and Methods: In this prospective study, patients who underwent successful percutaneous coronary intervention were randomly assigned to a candesartan or zofenopril treatment. After randomization, echocardiographic indices of cardiac remodeling including left ventricular mass, left ventricular mass index, and relative wall thickness were evaluated before the start of treatment along with 1-and 6-month follow-ups.Results: According to our study, candesartan group showed significant reduction of estimated left ventricular mass and left ventricular mass index at 6-month follow-up visit compared to baseline values (199.53±38.51 g vs. 212.69±40.82 g; 99.05 g/m 2 (90.00-116.5) vs. 106.0 g/m 2 (96.0~123.00), p<0.05, respectively). This trend was also observed in zofenopril group during the 6-month period (201.22±40.07 g vs. 207.52±41.61 g; 101.0 g/ m 2 (92.25-111.75.0) vs. 104.50 g/m 2 (95.0~116.75), p<0.05, respectively). Although both classes of drugs had favorable effects on post-myocardial infarction cardiac remodeling, the absolute benefit was more prominent in candesartan group as compared to zofenopril group (p<0.05). Conclusion: Our results suggest that candesartan treatment following myocardial infarction may potentially be useful in terms of improving postmyocardial infarction cardiac remodeling.

show abstract

“…This is especially important in chronically affected individuals with no overt clinical signs suggestive of known microbial infections. Such an approach, if supported by routinely used serum biomarkers namely, cardiac troponin I and T, creatinine kinase-MB, C-reactive protein, myoglobin, natriuetic peptides, and sST2 (Biomarkers, 2014;Nishimura et al, 2018;Coronado et al, 2019;Kottwitz et al, 2020) may have diagnostic value. A limitation of this approach is that the offending agents would be gone by that time, except being suspects, which may not alter treatment approaches to be followed clinically.…”

Section: Discussionmentioning

confidence: 99%

Triggers of Inflammatory Heart Disease

Lasrado

Yalaka

Reddy

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Inflammatory heart disease (IHD) is a group of diseases that includes pericarditis, myocarditis, and endocarditis. Although males appear to be more commonly affected than females, IHD can be seen in any age group. While the disease can be self-limiting leading to full recovery, affected individuals can develop chronic disease, suggesting that identification of primary triggers is critical for successful therapies. Adding to this complexity, however, is the fact that IHD can be triggered by a variety of infectious and non-infectious causes that can also occur as secondary events to primary insults. In this review, we discuss the immunological insights into the development of IHD as well as a mechanistic understanding of the disease process in animal models.

show abstract

Biomarkers in Cardiology - Part 1 - In Heart Failure and Specific Cardiomyopathies

Cited by 8 publications

References 47 publications

Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure

Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure

Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients

Triggers of Inflammatory Heart Disease

Contact Info

Product

Resources

About